TIBEAY Biosciences is a Dutch clinical-stage biopharmaceutical company developing Ronopterin, a first-in-class small molecule for early, first-line treatment of moderate to severe traumatic brain injury (TBI) — a condition associated with high mortality and long-term neurological impairment.

Ronopterin targets nitric oxide–mediated secondary injury by selectively inhibiting inducible nitric oxide synthase (iNOS), aiming to reduce progressive tissue damage in the acute phase following trauma. By intervening early in the injury cascade, the therapy seeks to improve functional outcomes in a patient population with significant unmet medical need.

Ronopterin has been evaluated in clinical studies in critically ill TBI patients, establishing a foundation for late-stage development. The company is preparing for a Phase 3b clinical trial in a clearly defined patient population with validated clinical endpoints.